National Drug-Eluting Stent Registry Needed – JAMA Editorial
This article was originally published in The Gray Sheet
Executive Summary
Divergent results from two registries of off-label coronary interventions with drug-eluting stents illustrate the need for a national, standardized registry, according to an editorial in the May 9 Journal of the American Medical Association.
You may also be interested in...
NEJM Articles Fuel Debate On Drug-Eluting-Stent Safety
Results of a Swedish registry of almost 20,000 patients, published in the New England Journal of Medicine, are adding fuel to the ongoing debate on drug-eluting-stent safety
U.S. DES Use Will Stabilize At Already Lowered Rates, Physicians Suggest
Recommendations by an FDA advisory panel earlier this month will likely reinforce, but not amplify, already moderated usage patterns of drug-eluting stents in the U.S., doctors suggest
Off-Label Drug-Eluting Stent Data Weak; Label Should Be Revised – Panel
FDA panel members recommended changes to drug-eluting stent labeling that would more clearly indicate differences between on- and off-label use. However, they found that the data was insufficient to make definitive conclusions about risks for unapproved applications, which account for the majority of stent placements